サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1757872

幹細胞による軟骨再生の世界市場

Stem Cell Cartilage Regeneration

出版日
ページ情報
英文 225 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
幹細胞による軟骨再生の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 225 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

幹細胞による軟骨再生の世界市場は2030年までに7億9,860万米ドルに達する見込み

2024年に4億7,640万米ドルと推定された幹細胞による軟骨再生の世界市場は、2030年には7億9,860万米ドルに達し、分析期間2024-2030年のCAGRは9.0%で成長すると予測されます。本レポートで分析したセグメントの一つである造血幹細胞は、CAGR10.4%を記録し、分析期間終了時には5億780万米ドルに達すると予測されます。多能性幹細胞セグメントの成長率は、分析期間中CAGR 6.4%と推定されます。

米国市場は1億2,520万米ドルと推定、中国はCAGR 8.6％で成長すると予測

米国の幹細胞による軟骨再生市場は、2024年に1億2,520万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億2,680万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.6%となります。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.4％と7.5％と予測されています。欧州では、ドイツがCAGR約7.0%で成長すると予測されています。

世界の幹細胞による軟骨再生市場- 主要動向と促進要因まとめ

幹細胞療法が軟骨再生の革新的なソリューションとして台頭しているのはなぜか？

軟骨は無血管性、無神経性、低細胞性であるため、再生能力は限定的です。軟骨損傷に対する従来の治療法-マイクロフラクチャー、骨軟骨移植、合成インプラントなど-は、特に若年で活動的な人においては、しばしば長期的に最適とはいえない結果をもたらします。幹細胞を用いた軟骨再生は、損傷した関節軟骨を修復し、人工関節置換術の必要性を遅らせる、あるいは排除する可能性のある、生物学的に駆動された低侵襲的なアプローチとして注目を集めています。

幹細胞、特に間葉系幹細胞（MSC）は、軟骨分化能と免疫調節能を有し、軟骨再生の理想的な候補となります。これらの細胞は、骨髄、脂肪組織、滑液から自家採取し、in vitroで増殖させ、欠損部位に直接注入したり、組織工学用の足場に播種したりすることができます。機能改善、疼痛軽減、軟骨構造修復を支持する臨床的エビデンスが蓄積されるにつれて、幹細胞を用いた治療法は整形外科やスポーツ医学の現場において浸透しつつあります。

細胞治療とバイオマテリアル・プラットフォームは、軟骨修復戦略をどのように前進させているのか？

幹細胞の調製、送達、統合における最近の技術革新は、再生整形外科の新たなフロンティアを牽引しています。同種幹細胞源や既製品は、拡張性を向上させ、治療期間を短縮するために開発されています。エクソソームや条件付き培地療法などの無細胞アプローチは、再生シグナル伝達能力を保持したまま、より免疫原性の低い代替療法として研究されています。規制に準拠したバイオプロセス技術や凍結保存技術は、一貫したGMPグレードの細胞製品を可能にしています。

これと並行して、ハイドロゲル、コラーゲンマトリックス、合成ポリマーなどの生体材料足場と幹細胞を組み合わせることで、三次元的な組織再構築が可能になりつつあります。これらの足場は、細胞の保持、増殖、軟骨分化を構造的、生化学的にサポートする役割を果たします。高度なドラッグデリバリー機構が足場システムに組み込まれ、炎症を調節し、成長因子を放出し、長期的な組織統合を改善しています。このような多面的なアプローチにより、幹細胞単体の注入を凌駕する軟骨再生の結果が得られつつあります。

どのような患者層やヘルスケアシステムで臨床導入が進んでいるのか？

主な患者層は、局所的な軟骨欠損、早期の変形性関節症（OA）、外傷後の軟骨損傷などを持つ人々です。スポーツクリニックや整形外科病院は、関節温存を求めるアスリートや若年成人のために、幹細胞を用いた治療を採用する最前線にいます。膝関節、足関節、股関節、肩関節では、関節内幹細胞注射や足場を利用したインプラントが使用されており、回復時間を短縮する関節鏡視下手術が支持されています。

臨床への導入は、規制の枠組みが整備され、ヘルスケアのインフラが整っている地域で特に進んでいます。韓国と日本は幹細胞軟骨治療のパイオニア的存在であり、迅速な承認パスウェイと国の償還政策を活用しています。北米や西欧では、特にFDAやEMAのような規制当局が再生医療に対する適応経路を導入しているため、臨床試験や自家治療センターの拡大が進んでいます。新興市場では、次世代細胞療法を提供する医療観光ハブや統合型整形外科クリニックを通じて需要が伸びています。

幹細胞による軟骨再生市場の世界的成長の原動力は？

幹細胞による軟骨再生の世界市場の成長を牽引しているのは、軟骨損傷の発生率の増加、低侵襲な再生ソリューションへの嗜好の高まり、細胞治療科学の進歩です。活動的な人々の高齢化とスポーツ傷害の急増に伴い、生物学的修復方法に対する需要が急増しています。幹細胞療法は症状の緩和だけでなく、関節の構造的保存も期待できるため、個別化された整形外科治療計画において非常に魅力的です。

強力な臨床機運、規制の柔軟性、再生プラットフォームへの民間投資の拡大により、商業化が加速しています。バイオメカニクス、細胞生物学、およびバイオマテリアルにおける学際的研究は、治療効果と手技の再現性を高めています。世界のヘルスケアシステムが早期介入とQOLを優先する中、幹細胞による軟骨再生は、外科手術の負担を軽減し、長期的な関節の健康を改善する、耐久性があり、生物学的に整合したソリューションを提供し、整形外科の展望を再構築する態勢を整えています。

セグメント

幹細胞の種類（造血幹細胞、多能性幹細胞、間葉系幹細胞）;治療法（マイクロフラクチャー、骨軟骨移植、自己軟骨細胞移植、幹細胞注射）;エンドユーザー（病院、外来手術センター）

調査対象企業の例（注目の42社）

  • Athersys, Inc.
  • BioTissue
  • CellGenix GmbH
  • Celularity Inc.
  • EpiBone
  • Fate Therapeutics
  • Hy2Care BV
  • Japan Tissue Engineering Co., Ltd.
  • Lazzaro Medical
  • Mesoblast Limited
  • Osiris Therapeutics
  • Regenexx
  • ReLive Life Sciences
  • Sayenza Biosciences
  • Sparta Biomedical
  • Stemwell
  • Tissue Regenix Group
  • Vericel Corporation
  • Xintela AB
  • Zimmer Biomet Holdings, Inc.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP35823

Global Stem Cell Cartilage Regeneration Market to Reach US$798.6 Million by 2030

The global market for Stem Cell Cartilage Regeneration estimated at US$476.4 Million in the year 2024, is expected to reach US$798.6 Million by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Hematopoietic Stem Cells, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$507.8 Million by the end of the analysis period. Growth in the Pluripotent Stem Cells segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$125.2 Million While China is Forecast to Grow at 8.6% CAGR

The Stem Cell Cartilage Regeneration market in the U.S. is estimated at US$125.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$126.8 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Stem Cell Cartilage Regeneration Market - Key Trends & Drivers Summarized

Why Is Stem Cell Therapy Emerging as a Transformative Solution for Cartilage Regeneration?

Cartilage has a limited intrinsic capacity for regeneration due to its avascular, aneural nature and low cellularity. Conventional treatments for cartilage injuries-such as microfracture, osteochondral grafting, or synthetic implants-often yield suboptimal long-term outcomes, particularly in younger, active individuals. Stem cell-based cartilage regeneration is gaining traction as a biologically driven, minimally invasive approach to repair damaged articular cartilage and potentially delay or eliminate the need for joint replacement.

Stem cells-particularly mesenchymal stem cells (MSCs)-possess chondrogenic differentiation potential and immunomodulatory properties, making them ideal candidates for cartilage regeneration. These cells can be harvested autologously from bone marrow, adipose tissue, or synovial fluid, expanded in vitro, and injected directly into the defect site or seeded into scaffolds for tissue engineering. As clinical evidence accumulates supporting functional improvement, pain reduction, and structural cartilage repair, stem cell-based therapies are gaining ground in orthopedic and sports medicine settings.

How Are Cellular Therapies and Biomaterial Platforms Advancing Cartilage Repair Strategies?

Recent innovations in stem cell preparation, delivery, and integration are driving new frontiers in regenerative orthopedics. Allogeneic stem cell sources and off-the-shelf products are being developed to improve scalability and reduce treatment latency. Cell-free approaches-such as exosome or conditioned media therapy-are being explored as less immunogenic alternatives that retain regenerative signaling capacity. Regulatory-compliant bioprocessing techniques and cryopreservation technologies are enabling consistent, GMP-grade cell products.

In parallel, the combination of stem cells with biomaterial scaffolds-such as hydrogels, collagen matrices, and synthetic polymers-is enabling three-dimensional tissue reconstruction. These scaffolds serve as structural and biochemical support for cell retention, proliferation, and chondrogenic differentiation. Advanced drug delivery mechanisms are being embedded into scaffold systems to modulate inflammation, release growth factors, and improve long-term tissue integration. These multifactorial approaches are significantly enhancing cartilage regeneration outcomes beyond standalone stem cell injections.

Where Is Clinical Adoption Increasing Across Patient Demographics and Healthcare Systems?

The primary patient population includes individuals with focal cartilage defects, early-stage osteoarthritis (OA), or post-traumatic chondral injuries. Sports medicine clinics and orthopedic hospitals are at the forefront of adopting stem cell-based interventions for athletes and younger adults seeking joint-preserving solutions. Intra-articular stem cell injections and scaffold-based implants are being used in knee, ankle, hip, and shoulder joints, supported by arthroscopic delivery techniques that reduce recovery time.

Clinical adoption is particularly strong in regions with supportive regulatory frameworks and advanced healthcare infrastructure. South Korea and Japan have pioneered commercial stem cell cartilage therapies, leveraging accelerated approval pathways and national reimbursement policies. North America and Western Europe are expanding clinical trials and autologous treatment centers, especially as regulatory agencies like the FDA and EMA introduce adaptive pathways for regenerative medicine. In emerging markets, demand is growing through medical tourism hubs and integrative orthopedic clinics offering next-generation cell therapies.

What’s Driving the Global Growth of the Stem Cell Cartilage Regeneration Market?

The growth in the global stem cell cartilage regeneration market is driven by increasing incidence of cartilage damage, rising preference for minimally invasive regenerative solutions, and advancements in cell therapy science. As active populations age and sports injuries proliferate, demand for biologic repair methods is rising sharply. Stem cell therapies offer not only symptomatic relief but also the promise of structural joint preservation, making them highly attractive in personalized orthopedic treatment planning.

Strong clinical momentum, regulatory flexibility, and expanding private investment in regenerative platforms are accelerating commercialization. Cross-disciplinary research in biomechanics, cell biology, and biomaterials is enhancing therapeutic efficacy and procedural reproducibility. As global healthcare systems prioritize early intervention and quality-of-life outcomes, stem cell cartilage regeneration is poised to reshape the orthopedic landscape-offering durable, biologically aligned solutions that reduce surgical burden and improve long-term joint health.

SCOPE OF STUDY:

The report analyzes the Stem Cell Cartilage Regeneration market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Stem Cell Type (Hematopoietic Stem Cells, Pluripotent Stem Cells, Mesenchymal Stem Cells); Treatment (Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation, Stem Cell Injections); End-User (Hospitals, Ambulatory Surgery Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Athersys, Inc.
  • BioTissue
  • CellGenix GmbH
  • Celularity Inc.
  • EpiBone
  • Fate Therapeutics
  • Hy2Care BV
  • Japan Tissue Engineering Co., Ltd.
  • Lazzaro Medical
  • Mesoblast Limited
  • Osiris Therapeutics
  • Regenexx
  • ReLive Life Sciences
  • Sayenza Biosciences
  • Sparta Biomedical
  • Stemwell
  • Tissue Regenix Group
  • Vericel Corporation
  • Xintela AB
  • Zimmer Biomet Holdings, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Stem Cell Cartilage Regeneration - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Osteoarthritis and Joint Degeneration Propels Demand for Regenerative Cartilage Therapies
    • Expansion of Sports Medicine and Orthopedic Treatments Throws the Spotlight on Stem Cell Applications
    • Innovation in Mesenchymal Stem Cell Harvesting and Differentiation Enhances Chondrogenic Potential
    • Growth in Biologic and Cell-Based Therapeutic Pipelines Accelerates Clinical Development Activities
    • Adoption of Scaffold-Free and 3D Bioprinted Cartilage Constructs Strengthens Regeneration Outcomes
    • Increasing Investment in Autologous and Allogeneic Stem Cell Banks Supports Therapeutic Readiness
    • Regulatory Advancements in Conditional Approvals and RMAT Designations Encourage Early Market Entry
    • Integration of Arthroscopic Delivery Techniques Improves Treatment Precision and Patient Recovery
    • Collaboration Between Biotech Firms and Academic Institutions Enhances Translational Research Pipelines
    • Development of Injectable Hydrogel and ECM-Based Carriers Expands Minimally Invasive Delivery Options
    • Growth in Stem Cell Manufacturing Infrastructure Strengthens GMP-Grade Production Scalability
    • Patient Demand for Joint Preservation Over Replacement Drives Interest in Regenerative Solutions
    • Expansion of Bioreactors and Cell Expansion Platforms Accelerates Commercial Viability
    • Differentiation Through Long-Term Pain Reduction, Functional Recovery, and Safety Profiles Enhances Market Competitiveness
    • Rising Use of iPSC and Adipose-Derived Stem Cells Fuels Donor Flexibility and Treatment Customization
    • Public and Private Research Funding Initiatives Strengthen Clinical Pipeline Maturity
    • Emphasis on Real-World Evidence and Post-Market Surveillance Supports Wider Clinical Adoption
    • Surge in Geriatric Orthopedic Care and Early Intervention Therapy Sustains Treatment Demand
    • International Collaborations and Cross-Border Trials Expand Patient Access and Regulatory Harmonization
    • Global Focus on Regenerative Orthopedics and Non-Implant Therapeutics Sustains Growth in Stem Cell Cartilage Regeneration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stem Cell Cartilage Regeneration Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stem Cell Cartilage Regeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Stem Cell Cartilage Regeneration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hematopoietic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hematopoietic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hematopoietic Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pluripotent Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pluripotent Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Pluripotent Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mesenchymal Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Mesenchymal Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Microfracture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Microfracture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Microfracture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Osteochondral Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Osteochondral Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Osteochondral Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Autologous Chondrocyte Implantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Autologous Chondrocyte Implantation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Autologous Chondrocyte Implantation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Stem Cell Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Stem Cell Injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Stem Cell Injections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • JAPAN
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • CHINA
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • EUROPE
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Stem Cell Cartilage Regeneration by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Stem Cell Cartilage Regeneration by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • FRANCE
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • GERMANY
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Stem Cell Cartilage Regeneration Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Stem Cell Cartilage Regeneration by Stem Cell Type - Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Stem Cell Cartilage Regeneration by Stem Cell Type - Percentage Breakdown of Value Sales for Hematopoietic Stem Cells, Pluripotent Stem Cells and Mesenchymal Stem Cells for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Stem Cell Cartilage Regeneration by Treatment - Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Stem Cell Cartilage Regeneration by Treatment - Percentage Breakdown of Value Sales for Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation and Stem Cell Injections for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Stem Cell Cartilage Regeneration by End-user - Hospitals and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for Stem Cell Cartilage Regeneration by End-user - Percentage Breakdown of Value Sales for Hospitals and Ambulatory Surgery Centers for the Years 2015, 2025 & 2030

IV. COMPETITION